muraloncology.com - MURA Operating profit EBITDA
Mural Oncology plc (MURA) maintains an impeccable reputation for developing cutting-edge immunotherapeutic agents against tumors. Stable demand for treatment renders the business independent of GDP, and cash operating profit before deductions confirms this resilience. The 0.00 level captures the latest values of this metric. The company's environmental footprint is minimal due to digital documentation and strict control over the disposal of chemical reagents.
Mural Oncology - analytical breakdowns and key metrics (MURA)
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
- earnings and market ratios statistics:
MURA - Net Income|Expected Net Income Mural Oncology plc|MURA - Price to Earnings Ratio|Projected Price to Earnings Ratio Mural Oncology PLC|MURA - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Mural Oncology|MURA - Operating profit EBITDA|Net earnings per share for the last 12 months Mural Oncology|MURA - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months muraloncology.com|MURA - Earnings per share growth in current year|Net earnings per share growth forecast for next year Mural Oncology plc
- sales revenue and business income indicators:
Analysis of all company metrics:Mural Oncology plc
This metric reflects the aggregate cash flow from core operations before deducting tax and interest obligations, serving as a fundamental indicator of the issuer's operational efficiency and financial autonomy. For Mural Oncology plc (MURA), the absolute EBITDA level demonstrates the company's ability to monetize developments in cytokine therapy, allowing investors to assess the resilience of the business model against the costs of creating low-toxicity interleukins.
Who Mural Oncology plc competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|Operating profit before deduction of amortization erasca.com ERAS|Delcath Systems - Operating profit before deduction of amortization|Operating profit EBITDA Y-mAbs Therapeutics Inc YMAB|AURA - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization CADL (Candel Therapeutics)|ARAY: Operating profit EBITDA|SELLAS Life Sciences Group (SLS) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Actuate Therapeutics|Profit before payment of interest, taxes and amortization CTOR|Operating profit before deduction of amortization HURA (TuHURA Biosciences, Inc.)|TARA (Protara Tx) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Fate Therapeutics, Inc. FATE|Aadi Bioscience, Inc. (WHWK) - Profit before interest, taxes and amortization|TCRX - Profit before payment of interest, taxes and amortization|CSBR (Champions Oncology) - Operating profit before amortization|XBIT: Operating profit EBITDA|Operating profit before deduction of amortization CEL-SCI|Profit before payment of interest, taxes and amortization OS Therapies Incorporated|Profit before interest, taxes and amortization radiopharmtheranostics.com RADX|Profit before payment of interest, taxes and amortization Artiva Biotherapeutics, Inc. (ARTV)|Profit before payment of interest, taxes and amortization ANL (adlainortye.com)|Profit before payment of interest, taxes and amortization Veru Pharma VERU|Tempest Therapeutics Corp (TPST) - Profit before interest, taxes and amortization|Xilio - Operating profit EBITDA|Operating profit before depreciation charges Renovaro Inc. (RENB)|KAPA (kairospharma.com) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization OnKure Therapeutics (OKUR)|Operating profit before deduction of amortization GDTC|CRIS: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Apollomics, Inc. (APLM)|THAR: Profit before deduction of interest, taxes, depreciation and amortization|Profit before payment of interest, taxes and amortization Advanced Biomed ADVB|Genprex Inc. - Profit before payment of interest, taxes and amortization|Calidi Bio - Operating profit EBITDA|sunshinebiopharma.com (SBFM) - Operating profit before deduction of amortization|xeneticbio.com (XBIO) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization salariuspharma.com|Operating profit before deduction of amortization PPBT|Operating profit EBITDA AON|Profit before payment of interest, taxes and amortization BeOne Medicines (BGNE)|CKPT (Checkpoint Therapeutics Inc) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA ELEV (Elevation Oncology)|Operating profit EBITDA iCAD Inc. ICAD|Ikena - Operating profit EBITDA|Notable Labs Ltd (NTBL) - Operating profit before deduction of amortization|VIRX: Operating profit EBITDA|MorphoSys Corporation (MOR) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization NAYA Biosciences|Operating profit before amortization AAPGV (ascentage.com)
